BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Purchased by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. boosted its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 20.6% in the 3rd quarter, Holdings Channel reports. The firm owned 13,322 shares of the biotechnology company’s stock after acquiring an additional 2,277 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in BioMarin Pharmaceutical were worth $937,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Innealta Capital LLC acquired a new stake in shares of BioMarin Pharmaceutical in the second quarter valued at about $25,000. BOKF NA purchased a new position in BioMarin Pharmaceutical in the 2nd quarter worth approximately $31,000. Quent Capital LLC boosted its holdings in shares of BioMarin Pharmaceutical by 58.9% during the 2nd quarter. Quent Capital LLC now owns 391 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 145 shares during the last quarter. nVerses Capital LLC purchased a new stake in shares of BioMarin Pharmaceutical in the third quarter valued at approximately $28,000. Finally, Itau Unibanco Holding S.A. acquired a new stake in shares of BioMarin Pharmaceutical in the second quarter valued at approximately $47,000. Hedge funds and other institutional investors own 98.71% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Charles Greg Guyer sold 5,278 shares of BioMarin Pharmaceutical stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $66.37, for a total value of $350,300.86. Following the completion of the transaction, the executive vice president now owns 68,909 shares in the company, valued at approximately $4,573,490.33. This trade represents a 7.11 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.85% of the stock is owned by company insiders.

BioMarin Pharmaceutical Trading Down 1.6 %

Shares of BMRN stock opened at $65.60 on Friday. The stock has a market capitalization of $12.50 billion, a P/E ratio of 39.78, a price-to-earnings-growth ratio of 0.65 and a beta of 0.31. BioMarin Pharmaceutical Inc. has a fifty-two week low of $65.35 and a fifty-two week high of $99.56. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.62 and a current ratio of 4.27. The company has a 50 day moving average price of $71.24 and a 200 day moving average price of $79.38.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.55 EPS for the quarter, missing the consensus estimate of $0.78 by ($0.23). The business had revenue of $746.00 million during the quarter, compared to analyst estimates of $703.37 million. BioMarin Pharmaceutical had a return on equity of 8.53% and a net margin of 11.71%. The business’s revenue was up 28.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.26 EPS. Equities research analysts predict that BioMarin Pharmaceutical Inc. will post 2.47 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on BMRN. StockNews.com raised BioMarin Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Bank of America dropped their price objective on shares of BioMarin Pharmaceutical from $130.00 to $115.00 and set a “buy” rating for the company in a report on Tuesday, September 17th. Evercore ISI reduced their target price on shares of BioMarin Pharmaceutical from $115.00 to $105.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 30th. Sanford C. Bernstein dropped their price target on shares of BioMarin Pharmaceutical from $116.00 to $90.00 and set an “outperform” rating for the company in a research note on Tuesday, September 17th. Finally, Stifel Nicolaus reduced their price target on shares of BioMarin Pharmaceutical from $115.00 to $87.00 and set a “buy” rating on the stock in a research report on Tuesday, September 17th. Seven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, BioMarin Pharmaceutical has a consensus rating of “Moderate Buy” and a consensus target price of $94.16.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.